On August 9, 2022, the Superior Court approved four settlement agreements with several Defendants in the Opioid Class Action.
– a settlement agreement with Roxane Laboratories Inc. and Boehringer Ingelheim (Canada) Ltd. which provides for a full and final release of all claims against them, as well as against Hikma Labs Inc., in exchange for the payment of CAD $125,000.
– a settlement agreement with BGP Pharma ULC and Mylan Pharmaceuticals ULC which provides for a full and final release of all claims against them in exchange for the payment of USD $199,000.
– a settlement agreement with Merck Frosst Canada & Co. that provides for the full and final release from all claims against it in exchange for the payment of CAD $145,000.
– a settlement agreement with Sanis Health Inc. that provides for the full and final release from all claims against it in exchange for the payment of CAD $180,000.
The class action is not over, however, as the settlement agreements allow the Plaintiff to continue the Opioid Class Action against the other Defendants.
If you would like to learn more about the progress of the file or the Settlement Agreements, consult the page on the Opioid Class Action.
To understand your rights and how these settlements may affect you, please consult the complete notice to class members.
